RXRX Live signals | Maximize Profits with Getagraph.com

BUY 6857 min ago

@ $8.09

Issued: 15 Apr 2024 @ 12:16

Return: -9.09%

Previous signal: Apr 15 - 11:57

Previous signal: Sell

Return: -1.34 %

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Stats
Today's Volume	3.91M
Average Volume	6.30M
Market Cap	1.59B
EPS	$0 ( 2024-02-26 )
Next earnings date	( $-0.430 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.65
ATR14	$0.0180 (0.25%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-16	Borgeson Blake	Sell	11 447	Class A Common Stock
2024-04-17	Secora Michael	Buy	37 500	Class A Common Stock
2024-04-16	Secora Michael	Buy	37 500	Class A Common Stock
2024-04-17	Secora Michael	Sell	23 124	Class A Common Stock
2024-04-16	Secora Michael	Sell	25 000	Class A Common Stock

INSIDER POWER
38.49
Last 100 transactions
Buy: 2 818 975 \| Sell: 1 209 082

Volume Correlation

Long: 0.35 (neutral)

Short: 0.65 (weak)

Signal:(51.298) Neutral

Recursion Correlation

10 Most Positive Correlations
PLXP	0.893
LUMO	0.879
VIRX	0.876
FATE	0.874
STRC	0.867
HOOK	0.859
GROM	0.859
CLEU	0.857
SNCE	0.851
QTEK	0.85

10 Most Negative Correlations
XOMAO	-0.832
CCRC	-0.827
XOMAP	-0.825
LUNA	-0.824
ITMR	-0.821
LRFC	-0.821
ACAHU	-0.814
AVEO	-0.813
MICT	-0.813
BNIXU	-0.811

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Recursion Correlation - Currency/Commodity

-0.80
( moderate negative )

-0.81
( strong negative )

0.00
( neutral )

-0.81
( strong negative )

-0.67
( moderate negative )

0.81
( strong )

Recursion Financials

Annual	2023
Revenue:	$44.58M
Gross Profit:	$-6.51M (-14.61 %)
EPS:	$-1.580

Q4	2023
Revenue:	$10.89M
Gross Profit:	$-12.59M (-115.60 %)
EPS:	$-0.400

Q3	2023
Revenue:	$10.10M
Gross Profit:	$-775 000 (-7.67 %)
EPS:	$-0.430

Q2	2023
Revenue:	$11.02M
Gross Profit:	$1.63M (14.83 %)
EPS:	$-0.380

Financial Reports:

No articles found.

Recursion

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.